Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof: Patent #: 8,946,398
Research output: Patent
Standard
Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof : Patent #: 8,946,398 . / Gottwein, Judith Margarete (Inventor); Scheel, Troels Kasper Hoyer (Inventor); Purcell, Robert E (Inventor); Bukh, Jens (Inventor).
Patent No.: WO2011/038737. Feb 03, 2015.Research output: Patent
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - PAT
T1 - Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof
T2 - Patent #: 8,946,398
AU - Gottwein, Judith Margarete
AU - Scheel, Troels Kasper Hoyer
AU - Purcell, Robert E
AU - Bukh, Jens
PY - 2015/2/3
Y1 - 2015/2/3
N2 - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
AB - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses.
M3 - Patent
M1 - WO2011/038737
Y2 - 2012/07/26
ER -
ID: 140385038